Acute Traumatic Cervical Spinal Cord Injury Treatment Study (SCI): Examining Glyburide (RP-1127)

Official Title: Glyburide Opportunity for Spinal Cord Injury Protection (GOSCIP)


The purpose of this study is to determine the safety of using intravenous Glyburide (RP-1127) in patients with acute traumatic cervical spinal cord injuries (SCI).

Eligibility criteria:

- Age 18-70 years old
- Acute cervical SCI with ASIA Impairment Scale grade A, B or C
- Non-penetrating SCI at neurologic level from C4 to C8
- No cognitive impairment that would preclude an informed consent, including moderate or severe traumatic brain injury (GCS < 13)
- Initiation of RP-1127 bolus within 6 hours of injury
- No other life-threatening injury
- No evidence of sepsis

* Please contact study team for more detailed inclusion/exclusion criteria

Contact Information

Francis Farhadi
614) 366-4961